Lapointe N - Search Results

1

Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure.

Rouleau JL, Pitt B, Dhalla NS, Dhalla KS, Swedberg K, Hansen MS, Stanton E, Lapointe N, Packer M; Canadian Prospective RandOmized FlosequInan Longevity Evaluation Investigators. Rouleau JL, et al. Among authors: lapointe n. Am Heart J. 2003 May;145(5):926-32. doi: 10.1016/s0002-8703(02)94782-4. Am Heart J. 2003. PMID: 12766756 Clinical Trial.

2

Cardioprotective effects of vasopeptidase inhibitors.

Lapointe N, Rouleau JL. Lapointe N, et al. Can J Cardiol. 2002 Apr;18(4):415-20. Can J Cardiol. 2002. PMID: 11992135 Review.

3

Angiotensin receptor blockers: powerful evidence with cardiovascular outcomes?

Pourdjabbar A, Lapointe N, Rouleau JL. Pourdjabbar A, et al. Among authors: lapointe n. Can J Cardiol. 2002 May;18 Suppl A:7A-14A. Can J Cardiol. 2002. PMID: 12045788 Review.

4

Effects of pre-, peri-, and postmyocardial infarction treatment with omapatrilat in rats: survival, arrhythmias, ventricular function, and remodeling.

Lapointe N, Nguyen QT, Desjardins JF, Marcotte F, Pourdjabbar A, Moe G, Calderone A, Rouleau JL. Lapointe N, et al. Am J Physiol Heart Circ Physiol. 2003 Jul;285(1):H398-405. doi: 10.1152/ajpheart.01144.2002. Epub 2003 Mar 27. Am J Physiol Heart Circ Physiol. 2003. PMID: 12663265 Free article.

5

Meta-analysis of the effects of endothelin receptor blockade on survival in experimental heart failure.

Lee DS, Nguyen QT, Lapointe N, Austin PC, Ohlsson A, Tu JV, Stewart DJ, Rouleau JL. Lee DS, et al. Among authors: lapointe n. J Card Fail. 2003 Oct;9(5):368-74. doi: 10.1054/s1071-9164(03)00125-8. J Card Fail. 2003. PMID: 14583897 Review.

6

Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling.

Pourdjabbar A, Parker TG, Nguyen QT, Desjardins JF, Lapointe N, Tsoporis JN, Rouleau JL. Pourdjabbar A, et al. Among authors: lapointe n. Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1997-2005. doi: 10.1152/ajpheart.00671.2004. Epub 2004 Nov 11. Am J Physiol Heart Circ Physiol. 2005. PMID: 15539424 Free article.

7

Activation of vascular tissue angiotensin-converting enzyme (ACE) in heart failure. Effects of ACE inhibitors.

Lapointe N, Rouleau JL. Lapointe N, et al. J Am Coll Cardiol. 2002 Mar 6;39(5):776-9. doi: 10.1016/s0735-1097(01)01830-7. J Am Coll Cardiol. 2002. PMID: 11869840 Free article. No abstract available.

8

Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat.

Lapointe N, Blais C Jr, Adam A, Parker T, Sirois MG, Gosselin H, Clément R, Rouleau JL. Lapointe N, et al. J Am Coll Cardiol. 2002 May 15;39(10):1692-8. doi: 10.1016/s0735-1097(02)01837-5. J Am Coll Cardiol. 2002. PMID: 12020499 Free article.

9

Effects of the vasopeptidase inhibitor omapatrilat on peri- and postmyocardial infarction in Zucker lean rats.

Lapointe N, Parker TG, Tsoporis JN, Nguyen QT, Marcotte F, Adam A, Lou I, Rouleau JL. Lapointe N, et al. Can J Cardiol. 2005 Mar;21(3):291-7. Can J Cardiol. 2005. PMID: 15776120

10

Vasopeptidase inhibition peri- and post-MI in Zucker insulin resistant rats: effect on MI size, arrhythmias, remodeling, function and fetal gene expression.

Lapointe N, Nguyen QT, Desjardins JF, Tsoporis J, Marcotte F, Pourdjabbar A, Parker TG, Moe G, Adam A, Rouleau JL. Lapointe N, et al. Cardiovasc Drugs Ther. 2005 Oct;19(5):323-32. doi: 10.1007/s10557-005-4389-9. Cardiovasc Drugs Ther. 2005. PMID: 16382294

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

271 results

Search Page

Filters